Dazopride is an antiemetic agent; it significantly enhances gastric evacuation (approximately six times more potent than metoclopramide in gastric evacuation assays); it increases antral motility by enhancing the amplitude of antral contractions; it reduces emetic frequency compared to control groups; it antagonizes tetralin-induced emesis at 5 mg/kg (i.p.); and it abolishes or attenuates cisplatin-induced emesis at doses of 1.0–5.0 mg/kg (i.v.).